Low-grade Albuminuria and Risk Factors of Atherosclerosis in Children with in Type 1 Diabetes

Abstract

Aims: Microalbuminuria reflects generalized vascular dysfunction and the risk of cardiovascular disease. The study aim was to examine the relationship between low-grade albuminuria and the selected risk factors for atherosclerosis, markers of endothelial dysfunction and inflammation in diabetic children and adolescents.

Methods: In 154 children with diabetes duration of at least 5 years we assessed: HbA1c, lipid profile, apolipoproteins, lipoprotein (a), asymmetric dimethylarginine (ADMA), von Willebrand factor, fibrinogen, uric acid, cystatin C, creatinine, 24-h blood pressure monitoring (ABPM) and albuminuria.

Results: Median albuminuria in the whole group was 2.02 μg/min. No correlations were found between albuminuria and lipids, apolipoproteins, fibrinogen, von Willebrand factor, cystatin C and GFR, HbA1c, and uric acid. A significant negative correlation was found between AER and ADMA (R=−0.24, p=0.0023) and positive correlation with all ABPM variables: mean SBP (R=0.23, p=0.0049), mean DBP (R=0.24, p=0.0023), daytime MAP (R=0.31, p=0.0001), nocturnal MAP (r=0.31, p<0.0001) and with percentage of blood pressure dipping (R=−0.17, p=0.0323). A trend was noted for a positive correlation between albuminuria and Lp(a) (R=0.15, p=0.059) and BMI Z-score (R=0.14, p=0.089).

Children with albuminuria below 5 μg/min. had significantly lower level of fibrinogen (2.96±0.57 g/l vs. 3.29±0.66 g/l, p=0.0167) and mean 24-h systolic and diastolic blood pressure, mean day and nocturnal blood pressure in comparison to the subjects with higher albuminuria.

Conclusions: diabetic children with acceptable diabetes control but high-normal albuminuria together with higher level of Lp(a), fibrinogen and blood pressure may require more attention in terms of prevention of early macroangiopathy development.

Key words

albuminuria - cardiovascular risk - diabetic children

• References

• 1 Mogensen CE, Chachali A, Christensen CK et al. Microalbuminuria an early marker of renal involvement in diabetes. Uremia Invest 1985; 9: 85-89
• 2 Viberti GC, Hill RD, Jerrett RJ et al. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1982; 1: 1430-1432
• 3 Nazim J, Dziatkowiak H. Nefropatia u dzieci i młodzieży z cukrzycą typu 1. Ann Diagn Paediatr Pathol 1998; wyd. spec. Nr1: D57–D62
• 4 Koivisto VA, Stevens LK, Mattock M et al. Cardiovascular disease and its risk factors in IDDM in Europe. EURODIAB IDDM Complications Study Group. Diabetes Care 1996; 19: 689-697
• 5 Rossing P, Hougaard P, Borch-Johnsen K et al. Predictors of mortality in insulin dependent diabetes: 10 year observational follow-up study. BMJ 1996; 313: 779-784
• 6 Tuomilehto J, Borch-Johnsen K, Molarius A et al. Incidence of cardiovascular disease in type 1 (insulin-dependent) diabetic subjects with and without diabetic nephropathy in Finland. Diabetologia 1998; 41: 784-790
• 7 Messent JW, Elliott TG, Hill RD et al. Prognostic significance of microalbuminuria in insulin-dependent diabetes mellitus. A twenty-three year follow-up study. Kidney Int 1992; 41: 836-839
• 8 American Diabetes Association . Nephropathy in diabetes (position statement). Diabetes Care 2004; (Suppl.1) S79-S83
• 9 Mogensen CE, Vestbo E, Poulsen PL et al. Microalbuminuria and potential confounders. Diabetes Care 1995; 18: 572-581
• 10 Klausen K, Borch-Johnsen K, Feldt-Rasmussen B et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension and diabetes. Circulation 2004; 110: 32-35
• 11 Satchell SCD, Tooke JE. What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium?. Diabetologia 2008; 51: 714-725
• 12 National Cholesterol Education Program (NCEP): highlights of the report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics 1992; 89: 495-501
• 13 Korohoda P, Zachwieja K, Pietrzyk JA et al. GFR estimation based upon cystatin C concentration as a substance marker–proposal of the new formula. Przegląd Lekarski 2009; 66: 1020-1026
• 14 National High Blood Pressure Education program working group on high blood pressure in children and adolescents. Pediatrics 2004; 114: 555-576
• 15 Gołąb S, Chrzanowska M. Dziecko Krakowskie 2000. Poziom rozwoju biologicznego dzieci i młodzieży Miasta Krakowa. Krakow 2002;
• 16 Margeirsdottir HD, Larsen JR, Brunborg C et al. the Norwegian Study Group for Childhood Diabetes . High prevalence of cardiovascular risk factors in children and adolescents with type 1 diabetes: a population-based study. Diabetologia 2008; 51: 554-561
• 17 Dobrovolskienė R, Mockevičienė G, Urbonaitė B et al. The risk of early cardiovascular disease in Lithuanian diabetic children and adolescents: a type 1 diabetes register database based study. Diabetes Res Clin Pract 2013; 100: 119-125
• 18 Steigleder-Schweiger C, Rami-Merhar B, Waldhör T et al. Prevalence of cardiovascular risk factors in children and adolescents with type 1 diabetes in Austria. Eur J Pediatr 2012; 71: 1193-1202
• 19 Schwab KO, Doerfer J, Marg W et al. DPV Science Initiative and the Competence Network Diabetes mellitus. Characterization of 33 488 children and adolescents with type 1 diabetes based on the gender-specific increase of cardiovascular risk factors. Pediatr Diabetes 2010; 11: 357-363
• 20 Boger RH. Asymmetric dimethylarginine, an endogeneous inhibitor of nitric oxide synthase, explains the “L-arginine paradox” and acts as a novel cardiovascular risk factor. J Nutr 2004; 134: 2842S-2847S
• 21 Marcovecchio ML, Widmer B, Turner C et al. Asymmetric dimethylarginine in young people with Type 1 diabetes: a paradoxical association with HbA(1c). Diabet Med 2011; 28: 685-691
• 22 Anderssohn M, Schwedhelm E, Lüneburg N et al. Asymmetric dimethylarginine as a mediator of vascular dysfunction and a marker of cardiovascular disease and mortality: an intriguing interaction with diabetes mellitus. Diab Vasc Dis Res 2010; 7: 105-118
• 23 Enas EA, Chacto V, Senthikumar A et al. Elevated lipoprotein (a) – a genetic risk factor for premature vascular disease in people with and without standard risk factors; a review. Dis Mon 2006; 52: 5-50
• 24 De Simone M, Verrotii A, Cappa M et al. Lipoprotein (a) in childhood: correlations with family history of cardiovascular disease. J Endocrinol Invest 2003; 26: 414-419
• 25 Gallego PH, Gilbey AJ, Grant MT et al. Early changes in 24-hour ambulatory blood pressure are associated with high normal albumin excretion rate in children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2005; 18: 879-885
• 26 Marcovecchio ML, Dalton RN, Schwarze CP et al. Ambulatory blood pressure measurements are related to albumin excretion and are predictive for risk of microalbuminuria in young people with type 1 diabetes. Diabetologia 2009; 52: 1173-1181
• 27 Lee SH, Kim JH, Kang MJ et al. Implications of nocturnal hypertension in children and adolescents with type 1 diabetes. Diabetes Care 2011; 34: 2180-2185
• 28 Snell-Bergeon JK, West NA, Mayer-Davies EJ et al. Inflammatory markers are increased in youth with type 1 diabetes: the SEARCH Case-Control study. J Clin Endocrinol Metab 2010; 95: 2868-2876
• 29 Klein RL, Hunter SJ, Jenkins AJ et al. DCCT/EDIC STUDY GROUP. Fibrinogen is a marker for nephropathy and peripheral vascular disease in type 1 diabetes: studies of plasma fibrinogen and fibrinogen gene polymorphism in the DCCT/EDIC cohort. Diabetes Care 2003; 26: 1439-1448
• 30 Verrotti A, Greco R, Basciani F et al. vonWillebrand factor and its propeptide in children with diabetes. Relation between endothelial dysfunction and microalbuminuria. Pediatr Res 2003; 53: 382-386
• 31 Rewers MJ, Pillay K, de Beaufort C et al ISPAD Clinical Practice Consensus Guidelines 2014. Assessment and monitoring of glycemic control in children and adolescents with diabetes. Pediatr Diabetes 2014; 15 (Suppl.20) 102-114
• 32 Marcovecchio ML, Tossavainen PH, Heywood JJ et al. An independent effect of parental lipids on the offspring lipid levels in a cohort of adolescents with type 1 diabetes. Pediatr Diabetes 2012; 13: 463-469
• 33 Lepore G, Bruttomesso D, Bonomo M et al. Continuous subcutaneous insulin infusion is more effective than multiple daily insulin injections in preventing albumin excretion rate increase in Type 1 diabetic patients. Diabet Med 2009; 26: 602-608